Cancer Site | Event number | aHR (95% CI) | ||||
---|---|---|---|---|---|---|
Before-matching cohort | Matched cohort | Before-matching cohort | Matched cohort | |||
TNF inhibitor cohort (12,491.9 PY) | nbDMARD cohort (117,735.9 PY) | TNF inhibitor cohort (8884.8 PY) | nbDMARD cohort (8422.2 PY) | (130,227.8 PY) | (17,307.0 PY) | |
All cancer | 81 | 1769 | 58 | 131 | 0.492 (0.351, 0.688) | 0.379 (0.255, 0.563) |
Oropharyngeal cavity | 0 | 14 | 0 | 1 | - | - |
GI tract | 25 | 536 | 18 | 41 | 0.432 (0.235, 0.797) | 0.670 (0.367, 1.223) |
 Upper GI tract | 8 | 149 | 7 | 11 | 0.846 (0.296, 2.421) | - |
 Colon and rectum | 9 | 163 | 6 | 14 | 0.385 (0.132, 1.124) | - |
 Liver | 4 | 159 | 3 | 12 | 0.377 (0.088, 1.616) | - |
 Biliary tract | 6 | 106 | 3 | 5 | 0.372 (0.096, 1.436) | - |
Respiratory system | 19 | 308 | 13 | 13 | 0.762 (0.382, 1.522) | 1.371 (0.458, 4.109) |
Bone and soft tissue | 1 | 4 | 0 | 0 | 8.366 (0.325, 215.255) | - |
Skin | 2 | 57 | 1 | 4 | 0.159 (0.014, 1.858) | - |
 Melanoma | 1 | 5 | 0 | 0 | 0.126 (0.001, 20.528) | - |
 Non-melanoma | 1 | 52 | 1 | 4 | 0.505 (0.023, 11.019) | - |
Breast | 8 | 316 | 7 | 58 | 0.146 (0.045, 0.474) | 0.748 (0.090, 6.221) |
Gynecologic system | 8 | 95 | 6 | 7 | 1.970 (0.660, 5.883) | - |
Genitourinary system | 6 | 181 | 3 | 7 | 0.220 (0.059, 0.820) | - |
Central nervous system | 0 | 12 | 0 | 1 | - | - |
Endocrine system | 9 | 164 | 8 | 31 | 0.901 (0.331, 2.456) | 0.518 (0.078, 3.454) |
Hematologic system | 1 | 140 | 0 | 13 | 0.011 (0, 1.037) | - |
 Lymphoma | 0 | 58 | 0 | 6 | - | - |